--- title: "James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition" type: "News" locale: "en" url: "https://longbridge.com/en/news/294085325.md" description: "Incyte (NASDAQ:INCY) Executive Vice President James Michael Morrissey acquired stock options for 6,426 shares valued at approximately $54,524, as reported in a Form 4 filing on July 27. The exercise price is set at $116.69 per share. This insider transaction coincides with Incyte's stock rising 5.3% to $125.17. Incyte, a small-molecule drug developer, recently reported strong revenue growth and high gross margins." datetime: "2026-07-28T15:00:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294085325.md) - [en](https://longbridge.com/en/news/294085325.md) - [zh-HK](https://longbridge.com/zh-HK/news/294085325.md) --- # James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition **James Michael Morrissey**, EVP at **Incyte** (NASDAQ:INCY), reported acquisition of company stock options on July 27, according to a new SEC filing. **What Happened:** Uncovered in a Form 4 filing on Monday with the U.S. Securities and Exchange Commission, Morrissey, EVP at Incyte, executed an insider options move. This move consisted of acquiring stock options for 6,426 shares of INCY, granting Morrissey the right to purchase the company’s stock at an exercise price of $116.69 per share. The Tuesday morning market activity shows **Incyte** shares up by 5.3%, trading at $125.17. This implies a total value of $54,524 for Morrissey's 6,426 shares. ### Unveiling the Story Behind Incyte Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs. ### Incyte's Financial Performance **Revenue Growth:** Incyte's remarkable performance in 3 months is evident. As of 31 March, 2026, the company achieved an impressive revenue growth rate of **20.87%**. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector. **Interpreting Earnings Metrics:** - Gross Margin: With a high gross margin of 91.79%, the company demonstrates effective cost control and strong profitability relative to its peers. - Earnings per Share (EPS): Incyte's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 1.52. **Debt Management:** Incyte's debt-to-equity ratio is below the industry average. With a ratio of **0.01**, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors. **Evaluating Valuation:** - Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 16.8 is lower than the industry average, indicating potential undervaluation for the stock. - Price to Sales (P/S) Ratio: The current P/S ratio of 4.5 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance. - EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): At 10.57, Incyte's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation **Market Capitalization Analysis:** The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale. ### Why Pay Attention to Insider Transactions While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process. In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction. Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise. Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors. ### Transaction Codes To Focus On Examining transactions, investors often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A **P** in Box 3 denotes a purchase, while **S** signifies a sale. Transaction code **C** indicates the conversion of an option, and transaction code **A** denotes a grant, award, or other acquisition of securities from the company. Check Out The Full List Of Incyte's Insider Trades. _This article was generated by Benzinga's automated content engine and reviewed by an editor._ ### Related Stocks - [INCY.US](https://longbridge.com/en/quote/INCY.US.md) - [NVS.US](https://longbridge.com/en/quote/NVS.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md) ## Related News & Research - [Incyte Stock: Is Wall Street Bullish or Bearish?](https://longbridge.com/en/news/296231523.md) - [Incyte President, Global Head of R&D Pablo J. Cagnoni sells 10,803 shares for $1.3 million](https://longbridge.com/en/news/295969312.md) - [Scott Galloway says GLP-1 drugs are a 'silver bullet' for America's woes, if we're not 'stupid enough' to get in the way](https://longbridge.com/en/news/295999435.md) - [55,370 Shares in Incyte Corporation $INCY Bought by Summit Global Investments](https://longbridge.com/en/news/295999395.md) - [Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says](https://longbridge.com/en/news/296259275.md)